European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness

by Marie Weil
December 23, 2021
A A
Share on LinkedinShare on Twitter
  • There are no currently approved therapies impacting disease progression for the up to 8 million people suffering from geographic atrophy (GA)1,2
  • Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with GA
  • Potential to be the first therapy with sustained efficacy for a broad GA patient population 
  • Acquisition complements Novartis established expertise in retinal diseases and gene therapy and further builds position in ophthalmology gene therapy and optogenetics following acquisitions of Vedere Bio and Arctos Medical

Basel, December 22, 2021 — Novartis announced today that it entered into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics.

Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that leads to progressive and irreversible vision loss1. There are no approved treatments for GA, making it one of the most significant unmet needs remaining in retinal diseases2.

GT005 is designed as an AAV2-based, one-time investigational gene therapy for GA secondary to AMD that is delivered under the retina. GT005 aims to restore balance to an overactive complement system, a part of the immune system, by increasing production of the CFI protein. Complement overactivation can lead to inflammation that damages healthy tissues, and it has been strongly correlated with the development and progression of AMD3. The CFI protein regulates the activity of the complement system. It is believed that increasing CFI production could reduce inflammation, with the goal of preserving a person’s eyesight.

The safety and efficacy of GT005 for the treatment of GA secondary to AMD is currently being evaluated in a Phase 1/2 clinical trial and two Phase 2 clinical trials4,5,6. GT005 has received Fast Track designation from the U.S. Food and Drug Administration for the treatment of people with GA.

Gyroscope also has several additional assets in its pipeline in early discovery for retinal diseases.

“With our own pioneering research in ocular gene therapies and our experience gained from bringing Luxturna to inherited retinal dystrophy patients outside of the US, Novartis has a well-established expertise in ocular gene therapies that will position us well to continue developing this promising one-time treatment” said Marie-France Tschudin, President, Novartis Pharmaceuticals. “This acquisition is one more step forward in our commitment to delivering innovation in ophthalmology to treat and prevent blindness worldwide.”

Novartis will make an upfront payment of $800 million and potential additional milestone payments of up to $700 million. Closing of the transaction is subject to customary closing conditions including regulatory approvals. Until closing, Novartis and Gyroscope Therapeutics will continue to operate as separate and independent companies.

Tags: < Invest

Related Industries

Health

BD Opens New €4 Million R&D Centre in Dublin, Will Invest Additional €30 Million in Enniscorthy Manufacturing Plant

June 3, 2023
Health

RECKITT ANNOUNCES PATRICK SLY AS PRESIDENT OF HEALTH AND SUSAN SHOLTIS AS PRESIDENT OF NUTRITION

June 2, 2023
Health

Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology

June 2, 2023
Health

Merck Increases Global Commitment to Biosafety Testing With € 35 Million Investment in Scotland

June 1, 2023
Health

Philips launches AI-powered CT system to accelerate routine radiology and high-volume screening programs

May 18, 2023
Health

Siemens Healthineers opens state-of-the-art education and development center in Erlangen, Germany

May 18, 2023

OPPO Announces Kaká as Global Brand Ambassador for its UEFA Champions League Partnership

May 26, 2023

...

MAN to supply eTrucks to Duvenbeck for Volkswagen Group Logistics from 2024 onwards

May 12, 2023

...

All eyes on Italy as IHG Hotels & Resorts hails six new luxury and lifestyle hotels

May 11, 2023

...

PPG highlights coatings for battery electric vehicles at The Battery Show in Germany

May 20, 2023

...

ABB collaborates with Lhyfe and Skyborn on one of Europe’s largest renewable hydrogen projects

May 9, 2023

...

BD Opens New €4 Million R&D Centre in Dublin, Will Invest Additional €30 Million in Enniscorthy Manufacturing Plant

June 3, 2023

...

Nestlé announces retirement of Magdi Batato, Stephanie Pullings Hart appointed as next Head of Operations

May 24, 2023

...

Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology

May 11, 2023

...

Siemens Healthineers invests 80 million euros in new semiconductor factory in Forchheim

May 25, 2023

...

ENGIE inaugurates the biggest agrovoltaic park in Italy, which will help to power Amazon’s operations

May 27, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist